Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Langmuir ; 40(5): 2632-2645, 2024 02 06.
Artigo em Inglês | MEDLINE | ID: mdl-38252152

RESUMO

Four FeIII complexes of typical artificial siderophore ligands containing catecholate and/or hydroxamate groups of tricatecholate, biscatecholate-monohydroxamate, monocatecholate-bishydroxamate, and trihydroxamate type artificial siderophores (K3[FeIIILC3], K2[FeIIILC2H1], K[FeIIILC1H2], and [FeIIILH3]) were modified on Au substrate surfaces. Their abilities to adsorb microorganisms were investigated using scanning electron microscopy, quartz crystal microbalance, and AC impedance methods. The artificial siderophore-iron complexes modified on Au substrates (FeLC3/Au, FeLC2H1/Au, FeLC1H2/Au, and FeLH3/Au) showed the selective immobilization behavior for various microorganisms, depending on the structural features of the artificial siderophores (the number of catecholate and hydroxamate arms). Their specificities corresponded well with the structural characteristics of natural siderophores released by microorganisms and used for FeIII ion uptake. These findings suggest that they were generated via specific interactions between the artificial siderophore-FeIII complexes and the receptors on microorganism surfaces. Our observations revealed that the FeL/Au systems may be potentially used as effective microbe-capturing probes that can enable rapid and simple detection and identification of various microorganisms.


Assuntos
Compostos Férricos , Sideróforos , Sideróforos/química , Compostos Férricos/química , Ferro , Ácidos Hidroxâmicos , Transporte Biológico
2.
Inorg Chem ; 62(40): 16362-16377, 2023 Oct 09.
Artigo em Inglês | MEDLINE | ID: mdl-37738382

RESUMO

Two hybrid-type artificial siderophore ligands containing both catecholate and hydroxamate groups as iron-capturing sites, bis(2,3-dihydroxybenzamidepropyl)mono[2-propyl]aminomethane (H5LC2H1) and mono(2,3-dihydroxybenzamide-propyl)bis[2-propyl]aminomethane (H4LC1H2), were designed and synthesized. Iron(III) complexes, K2[FeIIILC2H1] and K[FeIIILC1H2], were prepared and characterized spectroscopically, potentiometrically, and electrochemically. The results were compared with those previously reported for iron complexes with non-hybridized siderophores containing either catecholate or hydroxamate groups, K3[FeIIILC3] and [FeIIILH3]. Both K2[FeIIILC2H1] and K[FeIIILC1H2] formed six-coordinate octahedral iron(III) complexes. Evaluation of the thermodynamic properties of the complexes in an aqueous solution indicated high log ß values of 37.3 and 32.3 for K2[FeIIILC2H1] and K[FeIIILC1H2], respectively, which were intermediate between those of K3[FeIIILC3] (44.2) and [FeIIILH3] (31). Evaluation of the ultraviolet-visible and Fourier transform infrared spectra of the two hybrid siderophore-iron complexes under different pH or pD (potential of dueterium) conditions showed that the protonation of K2[FeIIILC2H1] and K[FeIIILC1H2] generated the corresponding protonated species, [FeIIIHnLC2H1](2-n)- and [FeIIIHnLC1H2](1-n)-, accompanied by a significant change in the coordination mode. The protonated hybrid-type siderophore-iron complexes showed high reduction potentials, which were well within the range of those of biological reductants. The results suggest that the hybrid-type siderophore easily releases an iron(III) ion at low pH. The biological activity of the four artificial siderophore-iron complexes against Microbacterium flavescens and Escherichia coli clearly depends on the structural differences between the complexes. This finding demonstrates that the changes in the coordination sites of the siderophores enable close control of the interactions between the siderophores and receptors in the cell membrane.

3.
Clin Transl Gastroenterol ; 9(9): 181, 2018 09 19.
Artigo em Inglês | MEDLINE | ID: mdl-30228265

RESUMO

INTRODUCTION: Recently, the population of individuals with non-celiac gluten sensitivity (NCGS) who do not have celiac disease but show improved symptoms with a gluten-free diet, has increased. Enzyme replacement therapy using digestive enzymes is expected to improve the symptoms of NCGS and be sustainable, since gluten-related proteins that are indigestible by the digestive system have been considered triggers of NCGS. METHODS: We selected patients with NCGS by screening demographic interviews, as well as performing medical evaluations, anti-gluten antibody tests, and gluten challenge tests. We performed a single-blind and crossover clinical trial with these subjects using a gluten challenge with the enzyme mixture or a placebo. Our designed enzyme mixture contained peptidase, semi alkaline protease, deuterolysin, and cysteine protease derived from Aspergillus oryzae, Aspergillus melleus, Penicillium citrinum, and Carica papaya L., respectively. RESULTS: Administration of the enzyme mixture significantly decreased the change in the score of the symptom questionnaire before and after the gluten challenge compared with administration of the placebo in patients with NCGS without adverse events. In particular, the changes in the score of the gluten-induced incomplete evacuation feeling and headaches were significantly improved. The serum levels of interleukin (IL)-8, tumor necrosis factor (TNF)-α, andregulated on activation, normal T cell expressed and secreted (RANTES) in subjects were not significantly changed by gluten, as expected from previous studies, and the enzyme mixture did not affect these inflammatory markers. CONCLUSION: In this human clinical study, we demonstrated the efficacy of the enzyme mixture derived from microorganisms and papaya in improving the symptoms of NCGS.


Assuntos
Terapia de Reposição de Enzimas , Hipersensibilidade Alimentar/diagnóstico , Hipersensibilidade Alimentar/terapia , Glutens/efeitos adversos , Adulto , Idoso , Aspergillus/enzimologia , Proteínas de Bactérias/uso terapêutico , Carica/enzimologia , Estudos Cross-Over , Cisteína Proteases/uso terapêutico , Citocinas/sangue , Dieta Livre de Glúten , Digestão , Endopeptidases/uso terapêutico , Feminino , Hipersensibilidade Alimentar/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Penicillium/enzimologia , Peptídeo Hidrolases/uso terapêutico , Método Simples-Cego , Adulto Jovem
4.
Biosci Biotechnol Biochem ; 69(7): 1221-5, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16041122

RESUMO

Angiotensin III has been reported to exist in various animals and tissues. The physiological role, however, is still unclear except that brain angiotensin III is a central regulator of vasopressin release. In this study, angiotensin III as well as angiotensin II enhanced an increase in body weight of clam worms of Perinereis sp. under a hypo-osmotic condition and suppressed a decrease in body weight under a hyper-osmotic condition. When clam worms were treated with tetrachloroaurate (III) after angiotensin-treatment, these enhancing and suppressive effects of the angiotensins under hypo- and hyper-osmotic conditions were inhibited. In contrast, when clam worms were pretreated with tetrachloroaurate (III) before angiotensin-treatment, these effects of angiotensins were not inhibited. Since tetrachloroaurate (III) is a representative blocker of aquaporins, these results indicate that angiotensin III as well as angiotensin II regulates water flow through aquaporins in clam worms.


Assuntos
Angiotensina III/farmacologia , Angiotensina II/farmacologia , Anelídeos/efeitos dos fármacos , Aquaporinas/fisiologia , Água/metabolismo , Animais , Anelídeos/fisiologia , Aquaporinas/antagonistas & inibidores , Transporte Biológico/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Cloretos/farmacologia , Relação Dose-Resposta a Droga , Compostos de Ouro/farmacologia , Soluções Hipertônicas/farmacologia , Soluções Hipotônicas/farmacologia , Modelos Biológicos
5.
Peptides ; 26(12): 2452-7, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-15993982

RESUMO

Angiotensin III (Ang III) as well as angiotensin II (Ang II) suppressed body weight loss of the clam worm Perinereis sp. under a hyper-osmotic condition, and enhanced body weight gain under a hypo-osmotic condition. Under a drying condition where the water inflow from outside the body was eliminated, Ang II suppressed body weight loss, but Ang III did not. Under these conditions, angiotensins I, IV, and (1-7) had no effect, and saralasin blocked the effects of Ang II and Ang III. It is concluded that Ang II and Ang III upregulate body fluid volume of the clam worm via Ang II receptors in different ways.


Assuntos
Angiotensina III/farmacologia , Angiotensina II/farmacologia , Anelídeos/fisiologia , Peso Corporal/efeitos dos fármacos , Receptores de Angiotensina/metabolismo , Vasoconstritores/farmacologia , Angiotensina II/metabolismo , Angiotensina III/metabolismo , Animais , Líquidos Corporais/metabolismo , Osmose/efeitos dos fármacos , Receptor Tipo 2 de Angiotensina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...